Introduction
Prostate cancer is the most frequently diagnosed malignancy in males and the second leading cause of cancer-related death in men after lung cancer. In 2006, the American Cancer Society reported an expected total of 234,460 newly diagnosed prostate cancers and 27,350 prostate cancer-related deaths in the United States (1) . Despite significant advances in prostate cancer treatment, the survival rate for advanced stages of this particular cancer has not significantly improved during the past decade (2) . The high mortality rate observed in advanced prostate cancer patients is due to loss of androgen dependency for cancer cell growth that results in resistance to androgen ablation therapy (3) . Furthermore, standard treatment options for localized prostate cancer (surgical, radiation, and hormonal therapy) are associated with morbidities that often impair patient quality of life, such as urinary incontinence and sexual dysfunction (4) . Therefore, prostate cancer patients seek complementary and alternative medicine (CAM) modalities in hopes of halting or slowing disease progression to improve the general quality of life (5) . Recent surveys demonstrated that approximately 40% of prostate cancer patients utilize various CAM modalities as a component of therapy (6) .
PC-SPES, a proprietary herbal mixture, recently received significant attention in the general public as well as scientific and medical communities. PC-SPES contains Scutellaria baicalensis and seven other herbal extracts (7) . PC-SPES has been shown to reduce serum prostate-specific antigen (PSA) levels and proven effective in patients with both androgen-sensitive and androgen-resistant types of prostate cancer (7) (8) (9) . Importantly, all studies reported a >50% reduction of PSA levels in more than half of patients with advanced androgen-refractory prostate cancer. Unfortunately, PC-SPES was voluntarily removed from the consumer market by its manufacturers due to undeclared substance contamination (that is, warfarin and diethylstilbestrol; http://www. meb.unibonn.de/cancer.gov/CDR0000404384.html). In June 2002, four National Institutes of Health-sponsored PC-SPES-associated studies, one of which included a clinical trial, were placed on hold. Since then, three laboratory studies have resumed their investigations (http://nccam.nih.gov/ health/alerts/spes/).
S. baicalensis Georgi, also known as huang qin, or Chinese skullcap, has been used for thousands of years in traditional Chinese medicine as an antiinflammatory, antibacterial, and anticancer remedy to treat respiratory infections, gastrointestinal disorders, hepatitis, and cancer. Our recent study demonstrated that the raw extract of S. baicalensis inhibits cancer cell growth in different cell lines, including prostate, squamous cell, and breast cancers (10, 11) . We further demonstrated that the S. baicalensis extract decreased PGE 2 production via the suppression of cyclooxygenase-2 (COX-2) activity, which is often elevated in various types of cancers (10, 12, 13) .
Ample evidence supports involvement of the COX-2 pathway in prostate carcinogenesis via several mechanisms, including stimulation of tumor invasion factors, such as vascular endothelial growth factor (VEGF) expression (14) , release of matrix metalloproteinases (15) , facilitation of inflammation (16) , and possible contribution of the COX-2 product PGE 2 to enhanced cell proliferation (16, 17) . Uncontrolled cell proliferation that leads to cancer formation is caused by disruption of proper cell cycle regulation, a pivotal characteristic of cancer cells. Increased levels of the G 0 /G 1 checkpoint controlling cyclins D1 and E, and their associated protein kinases (cdks), concurrently with decreased levels of cdk inhibitors (Cip/Kip family), were reported in prostate cancer LNCaP cells (18) and in animal models (19) .
The purpose of this study is to evaluate S. baicalensis as an anti-prostate cancer agent both in vitro (in androgendependent and androgen-independent cell lines) and in vivo (in nude mice xenografted with prostate cancer cells) and to explore its ability to affect both COX-2 and cell cycle regulation pathways to further understand the molecular mechanism of its anti-prostate cancer activity. We hope the knowledge gained by our research will significantly contribute to the development of new and effective therapy for this deadly disease.
Materials and Methods

Chemicals and Drugs
The raw extract of S. baicalensis was prepared by boiling the dried root of the plant in water, followed by a spraydrying process of the resulting water extract. The powder form of the extract was obtained from E-Fang Pharmaceutical Company (Guangdong, China) and contains baicalin, wogonoside, and oroxylin A as major components. The extract was dissolved in culture medium to 20 mg/ml, vortexed at room temperature for 1 min, and incubated at 37
• C for 1 h while rotating before use. This solution was centrifuged at 5,000 rpm for 10 min to remove any insoluble ingredients. The supernatant was passed through a 0.22-µm filter for sterilization and diluted with culture medium to final concentrations of 0.04-0.8 mg/ml of S. baicalensis extract. The quality and authenticity of S. baicalensis were assessed using high-performance liquid chromatography (20) . For result consistency, the same batch was used throughout the entire study. A 10-mM stock solution of celecoxib {SC-58635; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1]-benzene-sulfonamide, Searle Research and Development, St. Louis, MO}, a selective COX-2 inhibitor, was prepared with dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO). PC-SPES (Lot# 5431060) in capsule form (320 mg per capsule) was purchased from Botanic Lab (Brea, CA). Because most published studies on PC-SPES were performed using ethanol as a solvent vehicle to dissolve the extract (21, 22) , we used both media as well as ethanol to dissolve S. baicalensis and PC-SPES to final concentrations of 0.0015-1.5 mg/ml, following the same preparation steps as described previously.
Cell Lines and Cell Culture
Two human prostate cancer cell lines, LNCaP (androgen dependent) and PC-3 (androgen independent), were purchased from American Type Culture Collection (Rockville, MD). These two cell lines represent the two major types of prostate cancer: androgen-dependent/sensitive and androgen-independent/insensitive prostate cancer cell populations, the latter more typical of advanced prostate cancer (23) . Both cell lines were maintained in RPMI 1640 medium containing 10% GIBCO TM fetal bovine serum (Invitrogen, Carlsbad, CA) at 37
• C in a humidified atmosphere of 5% CO 2 .
Cell Viability Assay
The percentage of growth inhibition was determined by employing a 3,4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT; Sigma) assay to measure viable cells. Cells (4 × 10 3 cells per well) were seeded onto a 96-well plate for 24 h, treated with various concentrations of S. baicalensis, and incubated for an additional 3 or 5 days at 37
• C. Subsequently, 10 µl of MTT at a concentration of 5 mg/ml was added to each well, and cells were incubated for an additional 4-6 h. The supernatant was aspirated, and 100 µl of DMSO was added to the wells to dissolve any precipitate present. The optical density was then measured at a wavelength of 570 nm using an EL X 800 plate reader (Bio-Tek Instruments, Winooski, VT).
Cell Cycle Analysis
Cells (1.5 × 10 5 cells per well) were plated onto six-well plates and incubated for 24 h at 37
• C. Various concentrations of S. baicalensis were added to the wells and incubated for an additional 3 days. Cells were then washed, pelleted, fixed with cold 70% ethyl alcohol for at least 30 min at -20
• C, and incubated with 100 µg/ml RNase A and 50 µg/ml propidium iodide in phosphate-buffered saline at room temperature for 30 min. Samples were immediately analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA). The percentage of cell cycle distribution was determined using Cell Quest Pro software (Becton Dickinson, Franklin Lakes, NJ).
Quantitation of Prostate-Specific Antigen
LNCaP cells, known to produce high levels of PSA (24) , were plated onto a six-well plate at a density of 1.5 × 10 5 cells per well. After a 24-h incubation period, the medium was replaced with fresh medium containing 50% growth inhibition concentration (IC 50 ) doses of S. baicalensis (0.15 mg/ml) or celecoxib (25 µM) .After 72 h of treatment, the medium was collected and centrifuged to eliminate detached cells. PSA level in 150 µl supernatant was determined using an AxSYM PSA Kit (Abbot Laboratories, Abbot Park, IL) according to manufacturer's instructions. PSAis expressed as nanograms per 10 6 cells.
PGE 2 Enzyme Immunoassay
To quantify the level of PGE 2 released into culture media, a competitive PGE 2 enzyme immunoassay was performed according to manufacturer's instructions (Amersham Pharmacia Biotech, Piscataway, NJ). Supernatants of control and S. baicalensis (0.075-0.3 mg/ml)-treated cells were collected, centrifuged at 2,500 rpm for 2 min, and stored at -70
• C until further analysis. Aliquots (50 µl) of each sample were assayed in triplicate. Optical density was measured at 450 nm on an EL X 800 plate reader (Bio-Tek Instruments). The minimal detectable concentration of PGE 2 by the assay is 50 pg/ml. PGE 2 is expressed as picograms per 10 6 cells. The effect of celecoxib and S. baicalensis on COX-2 activity was further examined using an intracellular arachidonic acid conversion assay (11, 25) . After a 24-h incubation of LNCaP or PC-3 cells, the medium was aspirated and replaced with fresh medium containing 0.15 mg/ml S. baicalensis or 25 µM celecoxib. Cells were incubated for additional periods of time, and the medium was aspirated. After washing the cells with medium, fresh medium containing 100 µM arachidonic acid (Cayman Chemical, Ann Arbor, MI) was added and incubated for an additional 30 min. PGE 2 in the medium was measured as described previously and expressed as picograms per milliliter of medium.
Western Blot Analysis
To assess dose-dependent protein expression change, LNCaP or PC-3 cells were treated for 72 h with various concentrations of S. baicalensis extract (0.05-0.8 mg/ml for COX-2 protein or 0.1-0.8 mg/ml for cyclin D1, cyclin B1, and cdk1 kinase). To assess time-dependent protein expression change, both cell lines were treated with a single dose of the S. baicalensis extract (0.4 mg/ml) for various times (12, 24, 48 , and 72 h). Cellular proteins were extracted using a buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, and 1X proteinase inhibitor cocktail (Roche Applied Science, Indianapolis, IN) (11) . Fifteen micrograms of protein was fractionated by electrophoresis through a 10% SDS polyacrylamide gel, and the proteins were transferred onto a nitrocellulose membrane. The membrane was blocked for 1 h in a blocking buffer containing 5% dry milk, 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.1% Tween-20 and then incubated with a polyclonal rabbit immunoglobulin G (IgG) anti-COX-2 antibody (1:400 dilution, Cayman Chemical) in the blocking buffer at 4
• C overnight. The membrane was further incubated with a secondary anti-rabbit antibody conjugated with horseradish peroxidase (Amersham, Arlington Heights, IL), and the specific protein was detected using a chemiluminescent method (Amersham) followed by autoradiography according to manufacturer's instructions. This procedure was repeated for the detection of cyclin D1 and cyclin B1 proteins, using polyclonal rabbit IgG antibodies at a 1:200 dilution (Santa Cruz Biotechnology, Santa Cruz, CA). For detection of cdk1 kinase (p34 Cdc2 ), a monoclonal mouse IgG 2a anti-cdk1 antibody (Santa Cruz Biotechnology) at a 1:200 dilution was used, followed by incubation with peroxidase-labeled anti-mouse antibody (Amersham) at a 1:10,000 dilution. The same membrane was then used to detect β-actin protein, using a monoclonal mouse IgG 2a anti β-actin antibody (Sigma) at a 1:10,000 dilution as described previously.
cdk1 Kinase Activity Assay PC-3 cells were treated for 72 h with various concentrations of S. baicalensis (0.1-0.8 mg/ml) in a dose-dependency study or with a single concentration of S. baicalensis (0.4 mg/ml) in a time-course study. Cellular proteins were extracted as described previously. One milligram of protein was further incubated with 2 µg of anti-cdk1 antibody (Santa Cruz Biotechnology) for 2 h at 4
• C, followed by incubation with 25 µl (25% agarose) of protein A-agarose beads (Santa Cruz Biotechnology) at 4
• C on a rotator overnight. After two sequential wash cycles with a lysis buffer and kinase buffer (50 mM TrisHCl, 10 mM MgCl 2 , and 1 mM dithiothreitol), the immunoprecipitate was resuspended in 30 µl kinase buffer containing 4 µg Histone H1 (cdk1 kinase substrate), 50 µM of unlabeled adenosine triphosphate (ATP), and 5 µCi of [γ - 32 P]ATP at 30
• C for 30 min. After the addition of 2X SDS loading buffer and heating at 100
• C for 5 min, the reaction products were separated on 12% SDS-polyacrylamide gel electrophoresis and visualized by autoradiography.
Animals and Treatment Protocol
Six-week-old male nude mice (NCR-nu/nu) were purchased from Taconic (Cincinnati, OH). Each animal received a single-bolus subcutaneous injection of 3 × 10 6 PC-3 cells to the right flank. After 1 wk of inoculation to allow for adequate tumor cell engraftment (average tumor mass ≈150 mm 3 ), the mice were randomized into two experimental groups (n = 5). The treatment group was given a 200-mg/kg dose of S. baicalensis extract dissolved in water by oral gavage once a day, five times per week for 7 wk. Mice were weighed, and tumor volume was assessed on a weekly basis. Tumor volume was measured by two perpendicular dimensions (long and short) using a caliper and calculated using the formula (a × b 2 )/2, where a is the larger and b is the smaller dimension of the tumor. Treatment and care of experimental animals were in accordance with the institutional guidelines of the Mount Sinai School of Medicine.
Results
Growth Inhibition Effect of Scutellaria Baicalensis on Prostate Cancer Cells
To determine the anti-prostate cancer activity of S. baicalensis extract, we performed in vitro growth inhibition assays on LNCaP and PC-3 cells. The rate of inhibition was determined as a percentage of viable treated cells compared with viable control cells. S. baicalensis displayed a dosedependent (Fig. 1A ) and time-dependent (Fig. 1B) growth inhibition in both cell lines. Although both LNCaP and PC-3 cells were sensitive to S. baicalensis, this effect was not equally observed. The androgen-independent PC-3 cells exhibited a slightly increased sensitivity. IC 50 was 0.15 mg/ml for LNCaP cells and 0.1 mg/ml for PC-3 cells after 3 days of incubation with S. baicalensis, and this 0.05-mg/ml difference remained after 5 days of treatment (data not shown). We then compared the effect of S. baicalensis and PC-SPES on the androgen-independent PC-3 cell line. On a weight-byweight basis (information on the percentage of S. baicalensis in PC-SPES is unavailable), S. baicalensis was more effective in growth inhibition (IC 50 = 0.16 mg/ml in medium and 0.06 mg/ml in ethanol) than PC-SPES (IC 50 = 0.38 mg/ml in medium and 0.1 mg/ml in ethanol), regardless of the solvent vehicle used (Fig. 1C) .
Finally, we analyzed the effect of S. baicalensis on the cell cycle distribution of both cell lines. Our results markedly differed for LNCaP and PC-3 cells. Compared with controls ( Fig. 2A and C) , S. baicalensis caused a significant G 0 /G 1 phase arrest with a concurrent decrease of the S and G 2 /M phases in LNCaP cells (Fig. 2B) . A different effect was observed in PC-3 cells, where S. baicalensis caused a significant G 2 /M arrest, concurrently increasing the S phase and decreasing the G 0 /G 1 phase (Fig. 2D) .
Inhibition of PSA Production in LNCaP Cells
PSA has been recognized as a biomarker for monitoring treatment response to prostate cancer. Therefore, we investigated whether S. baicalensis can inhibit PSA production. Our analysis demonstrated a high level of PSA production in LNCaP cells (196 ng per 10 6 cells) (Fig. 3) but not in PC-3 cells (data not shown), which is consistent with a previous report (26) . After 72 h of treatment with the IC 50 dose of S. baicalensis (0.15 mg/ml) and celecoxib (25 µM), PSA levels decreased to 75.5 and 51.2 ng per 10 6 cells, respectively, indicating a significant inhibition of PSA production. These results suggest that S. baicalensis suppresses the pathway controlling PSA synthesis, presumably via an androgen receptor. These results support the findings of a recent study that S. baicalensis components (baicalein, wogonin, beobaicalein, and skullcapflavone) can suppress PSA production as well as androgen receptor expression in LNCaP cells (27) .
Inhibition of COX-2 Activity and Expression
Increased levels of COX-2 and its product PGE 2 have been identified in prostate cancer cells. Therefore, we determined the level of PGE 2 in LNCaP and PC-3 cells and the effect of S. baicalensis on PGE 2 synthesis. We observed elevated concentrations of PGE 2 in both cell lines (Fig. 4A) , which support the findings of previous investigations (28, 29) . at a concentration of 0.075 mg/ml and in PC-3 cells starting at a concentration of 0.15 mg/ml. PGE 2 production continued to decline in both cell lines as S. baicalensis concentrations increased (up to 0.3 mg/ml).
To further investigate the mechanism by which S. baicalensis inhibits PGE 2 production, we examined its effect on COX-2 enzymatic activity using an intracellular arachidonic acid conversion assay that measures PGE 2 production after the addition of exogenous arachidonic acid to the newly replenished medium of treated cells. For comparison, a known COX-2 inhibitor, celecoxib, was included in this assay. By providing exogenous arachidonic acid, a COX-2 substrate, we sought to eliminate the effect of endogenous arachidonic acid release from the cell membrane due to intracellular protein kinase and/or phospholipase A 2 activities. Our results demonstrate a significant decrease of PGE 2 level in the presence of both S. baicalensis and celecoxib at IC 50 doses in both PC-3 and LNCaP cells during a 24-h time period (Fig. 4B and C) . For each cell line, the pattern of PGE 2 inhibition was similar for celecoxib and S. baicalensis, although a slight delay of inhibition by S. baicalensis in PC-3 cells (2-h lag period for S. baicalensis vs. immediate for celecoxib) was observed (Fig. 4C) . The level of decreased PGE 2 production was similar in both cell lines, that is, a drop of approximately 200 pg/ml (from 1,048 to 853 pg/ml for LNCaP cells and from 482 to 264 pg/ml for PC-3 cells). However, the inhibitory effect in LNCaP did not occur until 12 h after the addition of arachidonic acid (Fig. 4B) . These results strongly support our hypothesis that S. baicalensis inhibits PGE 2 synthesis through COX-2 activity.
We also investigated the effect of S. baicalensis on COX-2 expression using Western blotting (Fig. 5) . The effect of S. baicalensis treatment on COX-2 expression differed in two cell lines, for both time-course and dose-dependency studies. In PC-3 cells, which had a lower baseline COX-2 expression level than LNCaP cells, treatment with S. baicalensis induced COX-2 expression in a time-and dose-dependent manner ( Fig. 5A and B) . In contrast, treatment of LNCaP cells with S. baicalensis slightly decreased COX-2 expression (Fig. 5C  and D) . These results further suggested that decreased PGE 2 synthesis induced by S. baicalensis is likely due to the direct inhibition of enzymatic activity of COX-2 rather than its expression.
Effect on Cell Cycle-Regulating Molecules
Cell cycle analysis revealed that S. baicalensis treatment induced G 1 arrest for LNCaP cells and G 2 for PC-3. Therefore, we further evaluated the effect of S. baicalensis on cyclin D1 and cyclin B1 expression, two factors important for cell progression from the G 1 to S and the G 2 to M phases, respectively (Fig. 6) . When LNCaP cells were treated with various concentrations ofS. baicalensis, cyclin D1 expression decreased in a dose-dependent manner (Fig. 6A) . We also observed a steady decrease in cyclin D1 expression in the course of 72 h, which at the end dropped to undetectable levels (data not shown). No change in cyclin D1 expression was observed in PC-3 cells, as expected (Fig. 6C) . These results indicate that S. baicalensis suppresses the expression of cyclin D1 in LNCaP cells, resulting in G 1 -phase arrest.
When cyclin B1 was analyzed, its level of expression did not change in both cell lines (Fig. 6B and D) , although a marked G 2 /M-phase arrest in PC-3 cells was observed after treatment with S. baicalensis. Therefore, we further examined the expression of cdk1 protein kinase (p34 Cdc2 ), the catalytic subunit of the cyclin B1/cdk1 complex. Our results showed that treatment with different doses of S. baicalensis for 72 h resulted in a slight decrease of cdk1 expression in PC-3 cells (Fig. 7A) . Time-course studies confirmed the efficacy of this dose after 72 h of treatment (Fig. 7B) . As expected, no change in cdk1 expression in LNCaP cells was observed after treatment with S. baicalensis (Fig. 7E) . We then determined the effect of S. baicalensis on cdk1 kinase activity by analyzing the level of histone H1 phosphorylation, the substrate of the cyclin B1/cdk1 complex, using a kinase activity assay. We observed both a dose-and time-dependent decrease of cdk1 kinase activity in PC-3 cells after treatment with S. baicalensis ( Fig. 7C and D) . These results indicate that S. baicalensis inhibits primarily cdk1 kinase activity in PC-3 cells leading to the G 2 /M-phase arrest. 
Inhibition of Tumor Growth in PC-3-Xenografted Nude Mice
To confirm the anticancer activity of S. baicalensis in vivo, nude mice were subcutaneously inoculated with PC-3 cells and treated with S. baicalensis by oral gavage at a dose of 200 mg/kg of body weight once a day, five times per week for 7 wk. Our results demonstrated a significant inhibition of tumor growth in the treated mice compared with the untreated animals (Fig. 8) . Average tumor volume at Week 8 was Figure 8 . Inhibition of tumor growth in nude mice by Scutellaria baicalensis. One week after subcutaneous inoculation with PC-3 cells, mice were randomly assigned into two groups, five animals per group. In the treatment group, S. baicalensis was given orally at a dose of 200 mg/kg of body weight once a day, five times per week for 7 wk. (A) The tumor volume of each animal was measured every week, and the mean tumor volume ± SD (bars) is graphed against time (week). The arrow represents the starting week of S. baicalensis treatment. Data points represent mean tumor volume ± SD (bars) of mice. A comparison between control and treated tumor volumes at the 8th wk was performed using the Student's t-test. * P < 0.05 compared with the control group. (B) The body weight of each animal was also measured weekly and graphed against time (week). 3 ) for control mice, a 50% reduction of tumor mass (P < 0.05). At a dose of 200 mg/kg of S. baicalensis, there was no evidence of drug-related toxicity, suggesting that S. baicalensis is well tolerated by the animals.
mm
3 (95% confidence interval, CI = 166-448 mm 3 ) for treated mice and 600 mm 3 (95% CI = 406-794 mm
Discussion
S. baicalensis has been shown to have a broad spectrum of biological activities, including antiinflammatory (30) and anticancer (10) . The present study confirmed that S. baicalensis has a strong dose-dependent inhibitory activity against both androgen-dependent (LNCaP) and androgenindependent (PC-3) types of prostate cancer, with established IC 50 doses at 0.15 mg/ml for LNCaP cells and 0.1 mg/ml for PC-3 cells (Fig. 1A) . The ability to inhibit prostate cancer growth was further confirmed in our animal study (Fig. 8) . The ability of S. baicalensis extract to inhibit both androgen-dependent and androgen-independent prostate cancer cells is clinically relevant and important. It is clear that prostate cancers frequently develop resistance to a conventional therapeutic regimen including androgen ablation. Once the prostate cancer cells become androgen independent, clinical failure often occurs, with a median survival of 9-12 mo. Therefore, S. baicalensis may be effective for the treatment of both androgen-independent and androgendependent prostate cancers. These promising results support the future clinical trial of this herbal extract to determine its efficacy as an anti-prostate cancer agent.
It is worthy to note S. baicalensis is more effective than PC-SPES (Fig. 1C) , a popular herbal mixture for the treatment of prostate cancer that contains eight herbs including S. baicalensis. In support of our finding, a recent study demonstrated that S. baicalensis is one of the herbal components that inhibit prostate cancer cell growth (LNCaP) in vitro, and S. baicalensis is the only herbal component with antiandrogenic activity (27) . These results also demonstrated that S. baicalensis may be a viable alternative for PC-SPES, given the quality-control and adulteration concerns. The use of a single herb reduces the side effects and possible antagonistic interactions of multiple herbal mixtures and eliminates the quality-control issues, such as contamination, adulteration, and/or poor quality, that are associated with multiple herbal mixtures (20, 31) .
The anticancer activity of S. baicalensis may be derived from its ability to inhibit cancer cell proliferation. We did not observe increased apoptosis in both cell lines after treatment with S. baicalensis (data not shown). However, S. baicalensis caused arrest at different cell cycle phases in these two cell lines, that is, G 1 arrest for androgen-dependent LNCaP cells and G 2 arrest for androgen-independent PC-3 cells (Fig. 2) . At the molecular level, we demonstrated that S. baicalensis reduced expression of cyclin D1 in androgen-dependent LNCaP cells, which is responsible for the G 1 -to S-phase transition of the cell cycle (Fig. 6A) . In androgen-independent PC-3 cells, a significant change in cyclin D1 and B1 expression was not observed; however, a significant decrease in cdk1 kinase expression and activity after treatment with S. baicalensis was noted (Figs. 6 and 7) . These findings are consistent with a recent study showing that the major components of S. baicalensis (baicalein, wogonin, beobaicalein, and skullcapflavone) induce G 1 arrest for LNCaP and G 2 arrest for PC-3 cells (27) . However, it is unclear why S. baicalensis differentially affects these two prostate cancer cell lines. This may be due to different regulatory mechanisms of cell proliferation between these two cell lines. It has been shown that LNCaP and PC-3 cells exhibit significant difference in their gene expression patterns, particularly the androgen-related signal transduction pathways. Karan et al., using a microarray method, identified 34 up-regulated and 8 down-regulated genes in androgen-dependent cells compared with androgenindependent cells (32) . Therefore, although S. baicalensis acts on the same signal transduction pathway (that is, COX-2), the possibility exists that the downstream effect of COX-2 is different in these two cell lines (that is, G 1 vs. G 2 arrest).
The ability of S. baicalensis to affect cell cycle-regulating molecules is an important finding because elevated levels of cyclin D1 promote prostate cancer development by reducing its dependence on androgen stimulation (18) . Additionally, there is evidence that androgens may induce G 1 /S transition and thus contribute to cancer cell proliferation (19) . Increased expression of G 1 -phase kinases cdk2 and cdk4 and increased activity of cdk2 kinase were observed as a result of androgen stimulation as well as down-regulation of cdk4 inhibitor p16 (33) and cdk2 inhibitor p21 (34) . Changes in the expression of cell cycle-regulating genes, such as cyclins A and D, cdk2, and p21, were also observed in PC-SPES-treated prostate cancer cells (35) . Due to the critical role of these cell cycleregulating molecules in cancer development, these molecules have become important targets for drug development. For example, flavopiridol, a semisynthetic flavonoid derived from the bark of the Dysoxylum binectariferum plant indigenous to India, specifically targets cdks to block cell cycle progression at the G 1 /S and G 2 /M checkpoints (36) . S. baicalensis may prove to be a good candidate for this class of agent.
Although it is possible that S. baicalensis acts directly on cell cycle-regulating molecules, such as cyclin D1 and cdk1, it is also possible that S. baicalensis may act on other upstream cell cycle-regulating molecules. It has been shown that COX-2 and its product PGE 2 are important molecules in regulating prostate cancer cell development and progression, particularly during the early stages (37) . For example, in PC-3 cells, PGE 2 induced the immediate-early gene c-fos via the protein kinase A pathway by activating prostaglandin EP-2/4 receptors, whereas COX-2 stimulates VEGF expression, resulting in increased proliferation (38, 39) . Furthermore, COX-2-specific inhibitors celecoxib and nimesulide dramatically reduced the expression of androgen-inducible genes, such as PSA, as well as androgen receptor expression via suppression of their promoter activity (40) . Our results showed that both prostate cancer cell lines had increased COX-2 expression (Fig. 5 ) and increased PGE 2 production (Fig. 4) (more so in androgen-sensitive LNCaP cells), consistent with previous reports (28, 29) . S. baicalensis suppressed PGE 2 synthesis in both cell lines (Fig. 4A) , and the pattern of PGE 2 inhibition was similar for both celecoxib, a COX-2-specific inhibitor, and S. baicalensis (Fig. 4C) , indicating that S. baicalensis acts on COX-2 enzymatic activity directly. However, it is unclear why a delay of inhibition of PGE 2 synthesis in LNCaP cells was observed (Fig. 4B) . Analysis of COX-2 expression in both cell lines revealed either slightly decreased (LNCaP) or increased (PC-3) COX-2 expression (Fig. 5) , further supporting the notion that decreased PGE 2 synthesis resulted from direct inhibition of COX-2 activity. Although the crosstalk between COX-2/PGE 2 and cell cycle regulation (that is, cyclin D1 and cdk1) remains unclear, it is plausible that COX-2 and/or PGE 2 acts on cell cycle regulation through intermediate kinase pathways such as mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) (41) . It is interesting to note that both S. baicalensis and celecoxib can inhibit PSA production in LNCaP cells (Fig.  3) , suggesting that COX-2 also interacts with the androgen signal transduction pathway. In a phase II clinical trial, 92% of prostate cancer patients who received celecoxib treatment for 3 mo showed a significant reduction of PSA level, further confirming the regulatory relationship of COX-2 and PSA (42) . It is worthy to note that, although S. baicalensis inhibits androgen receptor expression (27) , the androgen signal pathway alone cannot explain its anti-prostate cancer activity because both androgen-dependent and androgen-independent prostate cancer cells are sensitive to S. baicalensis.
In summary, this study, together with others (27) , demonstrated that S. baicalensis, the major component of the mixed herbal formula PC-SPES, is responsible for its anti-prostate cancer activity. More importantly, it inhibits androgenindependent prostate cancer cells (PC-3) more strongly than it inhibits androgen-dependent cells (LNCaP), which could be a viable alternative to prostate cancer patients who fail to respond to conventional hormone-based treatment. Inhibition of PSA production in LNCaP cells not only proves that S. baicalensis can inhibit the androgen-dependent signal transduction pathway but also suggests that PSA can be used as an intermediate marker for monitoring the response to S. baicalensis treatment for future clinical trials. Mechanistically, S. baicalensis targets multiple cell proliferation pathways, including COX-2/PGE 2 , cyclin D1, and cdk1, resulting in the suppression of prostate cancer growth at the G 1 or G 2 phases. Future clinical study is necessary to determine its efficacy in prostate cancer patients.
